TS-003688 — This IP poses an extensive understanding of performing Adeno-Associated Virus (AAV) infusions and covers essential aspects, such as pre-infusion preparation, patient care, and medication administration. This knowledge base serves as a valuable resource for healthcare professionals involved in administering AAV-based therapies. AAV-based gene therapies hold immense promise in treating a variety of genetic disorders, ranging from rare diseases to more common conditions. The know-how provided in this IP equips medical practitioners with the expertise needed to conduct AAV infusions effectively and safely. By ensuring proper protocols and best practices are followed, it enhances the success rates of AAV therapy interventions, ultimately improving patient outcomes. Ongoing updates and refinements to the know-how will likely be necessary to incorporate emerging best practices and advances in AAV therapy. Future iterations could include supplementary materials such as instructional videos or interactive modules to enhance accessibility and effectiveness. The IP is positioned to benefit pharmaceutical companies, biotech firms, and healthcare institutions involved in AAV-based therapies. By ensuring adherence to standardized protocols, it mitigates risks associated with therapy administration, thereby enhancing product safety and bolstering consumer trust.